Overview of 671. Why Has There Been So Little Progress on Alzheimer’s Disease?
This episode of Freakonomics Radio (host Stephen Dubner) examines why decades and billions of dollars of Alzheimer’s research have produced little clinical progress. Through investigative reporting by Charles Piller (author of Doctored) and the whistleblowing and forensic work of neuroscientist Matthew Schrag, the episode documents widespread problems—image manipulation, irreproducible preclinical work, regulatory conflicts of interest, and a dominant research agenda centered on the amyloid cascade hypothesis—and explores how the field might move forward (including alternative theories such as vascular/waste-clearance contributions and practical measures like aggressive blood‑pressure control).
Key people and institutions
- Charles Piller — investigative journalist (Science Magazine), author of Doctored: Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer's. Led reporting that compiled dossiers on problematic papers and researchers.
- Matthew Schrag — neurologist/neuroscientist (Vanderbilt), independent research-integrity consultant, whistleblower and forensic image analyst.
- Othman Ghribi — (transcript: “Grebe”) former mentor to Schrag; coauthor on retracted rabbit/cholesterol papers; later taught at University of Texas Rio Grande Valley.
- Sylvain Lesné and Karen Ashe — coauthors of a highly influential 2006 Nature paper proposing toxic amyloid oligomers; Lesné’s work was later found to contain image irregularities and the paper was retracted.
- Hoau‑Yan (Hoau‑Yan / Haoyuan) Wang — CUNY researcher whose work with Cassava Sciences (Simufilam) drew allegations of image manipulation and falsified data; subject of DOJ/SEC actions.
- Cassava Sciences (Simufilam) — biotech that promoted an anti‑Alzheimer’s compound; faced whistleblower complaints, SEC settlement, internal controversies and halted clinical development.
- Eliezer Masliah — formerly head of NIA neuroscience division; Piller’s investigation found numerous image irregularities across many of his coauthored papers; Masliah left his post after the dossier surfaced.
- NIH, Office of Research Integrity (ORI), FDA — funder/regulator entities criticized for slow or opaque responses and conflicts of interest (the “revolving door”).
Major investigations / case studies (concise)
- Lesné & Ashe (2006 Nature paper): Proposed specific amyloid oligomers impair memory; images (Western blots, etc.) later showed signs of manipulation; paper retracted after investigations. The study had been highly influential in boosting the amyloid‑oligomer hypothesis.
- Cassava Sciences / Simufilam: Whistleblowers flagged pharmacology concerns and suspect image retouching. Piller and Schrag compiled dossiers; DOJ later indicted researcher(s) (charges ultimately dropped in 2025), Cassava paid $40M to the SEC to settle investor‑misleading claims, stopped Simufilam development, senior executives resigned, and the company rebranded.
- Othman Ghribi (earlier rabbit cholesterol studies and others): Schrag’s early work with Ghribi was implicated in doctored images; several joint papers were later retracted (including a rabbit study retracted in 2023).
- Eliezer Masliah: Forensic experts and Piller identified apparent image irregularities across dozens of Mosliah’s (Masliah’s) coauthored papers (132 papers flagged in a partial review). NIH announced personnel changes around the time Piller’s story was published.
What the reporters and scientists found (main problems)
- Image manipulation and reuse: Western blots, microscopy, and other image data were allegedly doctored, duplicated, intensity‑altered or reused across different experiments, changing the underlying “measured” data.
- Irreproducibility: Key preclinical findings could not be independently reproduced; some influential results rested on suspect data.
- Concentration of funding and attention on a single hypothesis: The amyloid cascade/amyloid‑oligomer hypothesis dominated research funding, clinical trials, and careers—potentially crowding out other approaches.
- Regulatory and institutional failures: Slow, opaque investigations by universities and federal bodies (NIH/ORI) and a revolving door between FDA reviewers and industry raised conflict‑of‑interest concerns.
- Human costs: Whistleblowers and investigators (e.g., Schrag) faced professional risks and backlash; trainees and collaborators were sometimes caught up despite limited roles.
Scientific implications and alternative views
- Amyloid is not irrelevant, but insufficient: Anti‑amyloid therapies (e.g., aducanumab/Aduhelm and other antibodies) may reduce amyloid burden but have shown only modest slowing of decline and carry risks (ARIA—brain swelling/bleeding). Few or no patients have meaningfully improved.
- Broader, multi‑factor models: Schrag and others promote reframing Alzheimer’s as a problem of failed brain “waste clearance” (multiple toxic products: amyloid, tau, etc.) and vascular health. Blood‑vessel degeneration may impede clearance; improving vascular health could be productive.
- Practical clinical signal: Aggressive blood‑pressure control has shown protective effects on cognition, especially early—an actionable, low‑cost area compared with high‑risk, expensive anti‑amyloid drugs.
Recommendations / action items (from themes in the episode)
- Diversify research funding: NIH and funders should allocate more resources to non‑amyloid hypotheses (vascular health, clearance mechanisms, lifestyle and environmental drivers).
- Strengthen research integrity: Journals, universities and funders should require better data preservation, raw‑data availability, routine image forensics, and reproducibility checks before major funding/trials.
- Reform conflict‑of‑interest practices: Tighter rules around FDA/reviewer industry ties and transparency about revolving‑door hires.
- Protect and support whistleblowers: Create safer, better‑resourced channels and incentives to surface and investigate scientific misconduct promptly.
- Prioritize low‑risk interventions with evidence: Promote vascular health (blood pressure control, pollution reduction, education/inequality mitigation, lifestyle factors) while continuing to pursue multiple therapeutic approaches.
Notable quotes from the episode
- “No one’s getting better with these drugs. Every scientist who works with them, every clinician, will say the same. If they don't, they're lying.” — a blunt characterization of clinical benefit from some anti‑amyloid drugs (as reported in the episode).
- “Cheaters tend to cheat.” — expressing the idea that patterns of manipulation often extend across a scientist’s body of work.
- “Trust must be earned.” — call for stronger institutional accountability alongside defense of scientific research.
Quick timeline (high level)
- 1990s–2000s: Amyloid cascade hypothesis dominates research agenda.
- 2006: Influential Lesné & Ashe Nature paper proposing toxic amyloid oligomers.
- 2006–2020s: Multiple influential papers and trials; some clinical anti‑amyloid approaches fail.
- 2022–2025: Whistleblower dossiers, forensic image analysis, Science reporting by Piller; retractions (e.g., Lesné paper), Cassava/Simufilam controversies, SEC settlement, DOJ actions, personnel changes at NIA labs; some charges later dropped.
- Present: Continued debate; limited clinical gains from anti‑amyloid drugs; calls to broaden research focus and strengthen integrity.
Bottom line
The episode argues that progress against Alzheimer’s has been hampered not only by scientific complexity but also by systemic problems: reproducibility failures, apparent data manipulation in influential preclinical studies, concentrated funding toward a single dominant hypothesis, and regulatory/institutional shortcomings. The conversation does not reject amyloid entirely, but urges a pluralistic, better‑regulated research strategy that includes vascular and waste‑clearance perspectives and practical public‑health measures (e.g., blood‑pressure control), while reforming how science is funded, validated, and regulated.